RJA
CYTR

Raymond James & Associates’s CytRx Corp CYTR Stock Holding History

Raymond James & Associates’s Portfolio CYTR Stock Details CYTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,607
Closed -$12K – 3811
2018
Q2 		$12K Buy
10,607
+228
+2% +$341 ﹤0.01% 3519
2018
Q1 		$17K Hold
10,379
– – ﹤0.01% 3395
2017
Q4 		$18K Buy
10,379
+830
+9% +$1.72K ﹤0.01% 3353
2017
Q3 		$23K Buy
9,549
+837
+10% +$2.83K ﹤0.01% 3306
2017
Q2 		$33K Sell
8,712
-2,955
-25% -$10.1K ﹤0.01% 3214
2017
Q1 		$31K Buy
11,667
+5,834
+100% +$14.8K ﹤0.01% 3181
2016
Q4 		$13K Buy
5,833
+2,500
+75% +$7.35K ﹤0.01% 3179
2016
Q3 		$12K Hold
3,333
– – ﹤0.01% 3163
2016
Q2 		$45K Buy
3,333
+1,083
+48% +$18K ﹤0.01% 2881
2016
Q1 		$36K Buy
+2,250
New +$30.7K ﹤0.01% 2814

Other funds holding CYTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FI
FormulaFolio Investments Grand Rapids, Michigan $299M AUM 27.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AlphaStar Capital Management Cornelius, North Carolina $1.57B AUM 20.25% 1-Year Est. Return

Raymond James & Associates's CYTR Position: Q3 2018 in Review

Raymond James & Associates sold out of CytRx Corp (CYTR) in Q3 2018, closing a stake of 10,607 shares — an estimated $12K sold.

Raymond James & Associates first reported a position in CYTR in Q1 2016 and held it in 10 quarters. The position peaked at $45K in Q2 2016. 40 funds tracked by Wall St. Rank hold CYTR as of Q3 2018.

  • Raymond James & Associates reported no remaining CytRx Corp position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 10,607 CytRx Corp shares in Q3 2018, an estimated $12K.
  • Raymond James & Associates first reported a position in CytRx Corp in Q1 2016 and held it in 10 quarters.
  • Raymond James & Associates's CytRx Corp position peaked at $45K in Q2 2016.
  • 40 funds tracked by Wall St. Rank held CytRx Corp as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.